RxDoctor Payments Data

Nathan Thomas

Family Medicine · Des Moines, IANPI 1881044089

Payments from drug & device makers

$1,122in general payments, 2019–2025

Across 45 payments — averaging $24.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$191
  • AbbVie$146
  • Lilly USA, LLC$143
  • Insulet Corporation$89
  • Intuitive Surgical$81
  • Abbott$72
  • plus $401 from 11 others

What the payments were for

  • Food & beverage$1,122100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,122 in reported general payments places this provider in the 80th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$217,188
Medicare patients
431
Services billed
6,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide223$234,739
MounjaroTirzepatide170$204,662
EliquisApixaban217$172,312
FarxigaDapagliflozin Propanediol129$152,270
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/777$130,578
JardianceEmpagliflozin88$103,540
TrulicityDulaglutide61$82,530
XareltoRivaroxaban88$64,842
Humalog Kwikpen U-200Insulin Lispro24$58,424
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$49,591
FiaspInsulin Aspart (Niacinamide)31$34,330
Tresiba Flextouch U-100Insulin Degludec70$30,487
KerendiaFinerenone36$28,693
LinzessLinaclotide43$26,233
MyrbetriqMirabegron34$21,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$143$299,160282 claims
Novo NordiskOzempic, Fiasp$64$269,068254 claims
PfizerEliquis$18$172,312217 claims
Boehringer IngelheimJardiance, Tradjenta$16$110,893116 claims
AbbVieLinzess, Vraylar$146$48,03456 claims
BayerKerendia$191$28,69336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →